Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
Τίτλος | Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Konstas, A. G. P., Quaranta L., Katsanos A., Riva I., Tsai J. C., Giannopoulos T., Voudouragkaki I. C., Paschalinou E., Floriani I., & Haidich A-B. |
Journal | Br J Ophthalmol |
Volume | 97 |
Issue | 12 |
Pagination | 1510-5 |
Date Published | 2013 Dec |
ISSN | 1468-2079 |
Λέξεις κλειδιά | Aged, Antihypertensive Agents, Female, Glaucoma, Open-Angle, Humans, Intraocular Pressure, Male, Middle Aged, Ocular Hypertension, Preservatives, Pharmaceutical, Prospective Studies, Prostaglandins F, Prostaglandins F, Synthetic, Treatment Outcome |
Abstract | AIM: To compare 24 h intraocular pressure (IOP) control obtained with preservative free (PF) tafluprost 0.0015% versus branded preservative containing latanoprost 0.005% administered as first choice monotherapy in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT).METHODS: This prospective, observer-masked, crossover study included consecutive newly diagnosed patients with POAG or OHT, and baseline IOP between 24 and 33 mm Hg. Qualifying patients underwent baseline untreated 24 h IOP monitoring in habitual positions, with Goldmann tonometry at times 10:00, 14:00, 18:00 and 22:00, and Perkins supine tonometry at times 02:00 and 06:00. They were then randomised to either latanoprost or tafluprost, administered in the evening, for 3 months and then switched to the opposite therapy for another 3 months. 24 h monitoring was repeated at the end of each treatment period.RESULTS: 38 patients completed the study. Mean untreated 24 h IOP (24.9 mm Hg) was significantly reduced with both prostaglandins (p<0.001). Tafluprost demonstrated similar mean 24 h efficacy compared with latanoprost (17.8 vs 17.7 mm Hg; p=0.417). Latanoprost demonstrated significantly better 24 h trough IOP (15.9 vs 16.3 mm Hg; p=0.041) whereas tafluprost provided significantly lower 24 h IOP fluctuation (3.2 vs 3.8 mm Hg; p=0.008). No significant difference existed between the two prostaglandins for any adverse event.CONCLUSIONS: PF tafluprost achieved similar 24 h IOP reduction to branded latanoprost. The current study highlights the importance of complete assessment of efficacy over 24 h.CLINICAL TRIALS REGISTRATION: NCT01162603. |
DOI | 10.1136/bjophthalmol-2012-303026 |
Alternate Journal | Br J Ophthalmol |
PubMed ID | 23681371 |